Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
12.58
+0.58 (4.83%)
Sep 4, 2025, 3:11 PM - Market open
Aurinia Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts that cover Aurinia Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $12.25, which forecasts a -2.62% decrease in the stock price over the next year. The lowest target is $9.00 and the highest is $17.
Price Target: $12.25 (-2.62%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 1, 2025.
Analyst Ratings
The average analyst rating for Aurinia Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $8 → $9 | Buy | Maintains | $8 → $9 | -28.46% | Aug 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +35.14% | Jul 30, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $10 | Buy | Reiterates | $10 | -20.51% | Sep 16, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $10 | Buy | Reiterates | $10 | -20.51% | Sep 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +3.34% | Sep 6, 2024 |
Financial Forecast
Revenue This Year
274.92M
from 235.13M
Increased by 16.92%
Revenue Next Year
314.20M
from 274.92M
Increased by 14.29%
EPS This Year
0.67
from 0.04
Increased by 1,570.25%
EPS Next Year
0.80
from 0.67
Increased by 19.08%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 286.9M | 374.8M | |||
| Avg | 274.9M | 314.2M | |||
| Low | 259.7M | 276.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 22.0% | 36.3% | |||
| Avg | 16.9% | 14.3% | |||
| Low | 10.4% | 0.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.85 | 1.28 | |||
| Avg | 0.67 | 0.80 | |||
| Low | 0.49 | 0.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2,026.3% | 91.7% | |||
| Avg | 1,570.2% | 19.1% | |||
| Low | 1,125.0% | -4.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.